The DAC Inhibitor LBH589 Is Highly Effective in Both “Therapy”-Sensitive and -Resistant Lymphomas and Enhances the Anti-Tumor Activity of Chemotherapy Agents, Monoclonal Antibodies, and Bortezomib
Maraj I, Hernandez-Ilizaliturri F, Chisti M, Czuczman M. The DAC Inhibitor LBH589 Is Highly Effective in Both “Therapy”-Sensitive and -Resistant Lymphomas and Enhances the Anti-Tumor Activity of Chemotherapy Agents, Monoclonal Antibodies, and Bortezomib. Blood 2008, 112: 4984. DOI: 10.1182/blood.v112.11.4984.4984.Peer-Reviewed Original ResearchPatient-derived tumour cellsB-cell lymphomaTarget proteinsAnti-tumor activitySequence of administrationNon-histone proteinsChemotherapy agentsCell linesTumor cellsMonoclonal antibodiesCellular processesTranscription factorsEffects of LBH589Gene transcriptionLymphoma cellsAlamar Blue reductionDeacetylasesMitochondrial potentialCell deathRituximab-resistant cell linesSchedule of administrationSignificant anti-tumor activityDAC activityPatient-derived tumor cellsNegative selection